Japan Coronary Stents Market 2026 – 2035

The Japan market size of coronary stents is estimated to be USD 1.68 billion in 2026 and it is expected to rise to about USD 2.40 billion in 2035 with the CAGR expected to be 4.2% during the period 2026-2035.

The market is growing due to the growing number of coronary artery diseases among the aging population, a surge in the number of lifestyle-acquired cardiovascular risk factors such as diabetes and hypertension, increased use of minimally invasive percutaneous coronary interventions in place of bypass surgery, innovative technology in designing drug-eluting stents and bioresorbable scaffolds, compelling reimbursement policies in support of PCI procedures and highly competitive production capacities of medical devices domestically.

Market Highlight

• Japan is one of the most sophisticated cardiovascular care markets in the world with the resultant advanced healthcare facilities and the latest stent technology.

• By type of product, the market is dominated by drug-eluting stents with bare metal stents keeping 34.0% of the market share in the year 2025 due to their affordability and reliability.

• By biomaterial, cobalt-chromium is the best with a 35.0% market share in 2025, which is preferred for the strength and flexibility of the material plus biocompatibility in all types of stents.

• By end user, 36.5% of the cardiac catheterization laboratories will be controlled in 2025 due to the agglomeration of knowledge and high volumes of PCI in cities.

• By region, Kyushu & Okinawa will grow the fastest at an estimated CAGR of 5.3% until 2035, due to the modernization of healthcare infrastructure and aging population.

• In Japan alone, the population above 65 years had a 28.0% in 2020 which is projected to rise to 35.3% in 2040 and is a continuous source of cardiovascular care demand.

Significant Growth Factors

The Japan Coronary Stents Market Trends present significant growth opportunities due to several factors:

• Rapidly Aging Population and Escalating Cardiovascular Disease Burden:

The demographic transition of Japan to a super-aged society is the key factor behind the coronary stents market as the population of individuals older than 65 years of age, which comprised 28.0% of the total population in 2020 and is expected to rise to 35.3% by 2040 as the overall population will have dropped to about 111 million. Heart disease and stroke rank among the cardiovascular diseases with serious impacts on life expectancy, and healthy life expectancy and the medical expenses of cardiovascular diseases are rising annually in Japan as the population is aging even as the age-adjusted mortality rates show that the treatment technologies are improving such as the use of coronary stents that enhance the duration of survival and dealing with more chronic cardiac patients annually.

The aged population has a massive burden of cardiovascular disease with around 5.4 million additional CVD deaths from 1990 to 2017 with Japan being the most affected country with the significantly high rate of demographic transition to old age where lifestyle-related risk factors such as hypertension, diabetes, obesity, and high cholesterol levels generate numerous comorbidities with aggressive cardiovascular approaches being necessary. Hundreds of thousands of Japanese patients perish annually due to acute myocardial infarction and chronic coronary artery disease with studies recording different regional patterns with urban areas including the Tokyo and Osaka metropolitan regions experiencing smaller decreases or leveling off of rates of mortality among middle-aged men aged 30-49 years compared to other regions, perhaps due to coronary heart disease incidence being increasing in relation to westernized lifestyles, dietary changes, lack of physical activity, and occupational stress.

The control of hypertension is still a significant cardiovascular risk factor in Japan, and significant decreases in the mean systolic blood pressure levels in the late 20th century contributed to the radical reductions in stroke mortality, yet current stagnation in blood pressure management and the emergence of undesirable changes in body mass index, physical activity, and dietary habits are threatening to halt cardiovascular disease progress unless countermeasures are applied like next-generation drug-eluting stents and bioresorbable scaffolds that show better outcomes. The percentage of heart failure is rising in comparison to acute myocardial infarction cases of the cardiovascular diseases cases, with about 1 to 2 million Japanese patients living with chronic heart failure and nearly 170,000 patients succumbing to heart diseases each year which is a significant amount of the population in need of coronary interventions such as stent implantation to avoid larger heart failure stages that would require more intensive and expensive care.

• Preference for Minimally Invasive Procedures and Advanced Healthcare Infrastructure:

A key market driver is the overwhelming patient and physician preference for the less invasive forms of percutaneous coronary interventions such as angioplasty and stent placement over the conventional coronary artery bypass grafting with sternotomy, cardiopulmonary bypass, and prolonged rehabilitation. The healthcare system in Japan is at the forefront of cardiac innovation and cardiac catheterization laboratories are everywhere with state-of-the-art imaging technologies such as intravascular ultrasound, optical coherence tomography, and fractional flow reserve measurement that allow the precise characterization of the lesion, optimal stent sizing and confirmation of successful deployment with limited complications.

Cardiac catheterization laboratories have a 36.5% market share in 2025 because of the concentrated expertise and high volumes of PCI in wider metropolitan areas where specialized centers use thousands of cases of interventions such as bifurcation stenting, chronic total occlusion revascularization and left main coronary artery. The catheterization laboratory ecosystem is complemented by hospitals and ambulatory surgical centers, with Japan continuing to build specialized cardiac facilities throughout the country to have wider geographic coverage as cardiovascular disease management is the key agenda of the Japanese National Plan, promoting measures against cerebrovascular and cardiovascular disease with the view of coordinating prevention, treatment and rehabilitation services by all 47 prefectures in the country. Development in outpatient coronary stenting reduces hospitalization, and same-day discharge or next-day discharge is becoming the new trend for uncomplicated cases using radial artery access, which does decrease bleeding complications and allows earlier mobilization, which reduces healthcare expenses and increases patient satisfaction over the traditional format of spending several days in a hospital.

The positive reimbursement of the procedure in Japan motivates patients and healthcare providers to adopt stent implantation procedures, national health insurance for the costs of PCI procedures eliminates financial barriers to access, and providers receive reasonable compensation to adopt high-quality technologies such as latest-generation drug-eluting stents and bioresorbable vascular scaffolds with higher procedure charges due to their improved clinical value.

What are the Major Advances Changing the Japan Coronary Stents Market Today?

• Bioresorbable Vascular Scaffolds and Temporary Support Platforms:

The potential benefit of bioresorbable vascular scaffolds is that they provide temporary mechanical support, which subsequently dissolves to allow elimination of long-term risks that permanent metallic implants could pose, and also enables restoration of the natural physiology of vessels and elimination of future surgery events such as bypass grafting or repeat percutaneous procedures at the same location. These entirely biodegradable implants normally use poly-L-lactic acid or magnesium alloys that give 6-12 months of scaffolding at a critical healing stage as arteries remodel then materials are normally degraded by hydrolysis or corrosion to metabolically eliminated by products and a healed vessel is left without any residual foreign material that may trigger late thrombotic events, neoatherosclerosis, or chronic inflammation.

Theoretical benefits of bioresorbable scaffolds encompass restored vasomotion to allow natural vessel expansion and constriction to physiological needs, removal of late stent thrombosis that cannot be resolved regardless of time in the presence of permanent metallic stents and the requirement of continuing antiplatelet therapy, non-invasive imaging that can be performed with CT and MRI without any artifacts and the ability to change future treatment options without the limitations of currently implanted hardware. The experience of clinical introduction of first-generation bioresorbable stents showed difficulties such as an increased incidence of acute thrombosis associated with increased strut thickness and footprints than the existing metallic drug eluting stents, scaffold fracture during clinical implantation or later due to mechanical stress, and premature bioresorption or incomplete degradation, which requires careful patient selection and precise technique of implantation.

The newer technologies of bioresorbable bioprostheses overcome the shortcomings of previous generation bioprostheses by using slimmer strut designs closer in diameter to those of metallic stents, better polymers with degradation kinetics that match vessel healing kinetics, greater radial strength to prevent acute recoil or late scaffold collapse, and more specialized delivery systems that allow finer control of deployment and thereby reduce procedural complications. The Japanese healthcare system comprised of well-trained interventional cardiologists and high-quality imaging can offer optimum conditions to the introduction of bioresorbable scaffolds, and the first adopter physicians will gain experience with patient selection criteria, implantation protocol, and long-term follow-up plans, which will be used to quantify clinical utility as products are matured and regulatory approvals are expanded.

• Precision Implantation Techniques and Advanced Imaging Integration:

The combination of advanced intravascular imaging tools such as optical coherence tomography and intravascular ultrasound with stent implantation procedures is a transformative practice change that allows accurate lesion evaluation, optimum device size, implantation verification, and complication detection that outweigh angiography-guided procedures based on two-dimensional contrast imaging. Optical coherence tomography is an imaging modality with near-microscopic resolution of coronary arteries and implanted stents that can be used to identify malapposition with stent struts not contacting vessel walls with creating thrombogenic surfaces, underexpansion with small balloon inflation leaving stents under-extruded against reference vessel diameter and disrupting flow and promoting restenosis, edge dissections with vessel injury at stent edges requiring extension coverage, and tissue protrusion with plaque extrusion through struts, which may embolize distally.

Complementary deep tissue penetration Intravascular ultrasound Intravascular ultrasound provides the vessel wall characteristics of plaque composition, calcium distribution and size of the external elastic lamina that allow the vessel sizing decision and optimal stent choice and studies have shown that imaging-guided PCI reduces major adverse cardiac events by 20-30% over angiography alone and the extra procedural time and cost is warranted by better clinical outcomes. The assessment of fractional flow reserve is used to measure pressure gradients in coronary stenoses used to quantify the hemodynamic importance of these lesions such that evidence-based decisions can be made as to whether a lesion needs to be revascularized or treated with optimal medical therapy alone and that the lesions that are being treated are those of functional importance. Robotic-assisted PCI systems developed in Japan capitalize on more advanced imaging with highly precise catheter control to allow complex interventions to be performed by less-experienced operators with reduced radiation exposure of the interventional staff as remote-controlled robots allow plans to be operated by the physician in shielded control stations with artificial intelligence providing real-time feedback on the best device choice, size, and placement based on the experience with thousands of previous cases.

• Domestic Manufacturing Excellence and Regulatory Environment:

The Japanese competitive medical device manufacturing industry that entails companies such as Terumo Corporation offers tremendous competitive advantages of locally developed stent technologies tailored to Japanese patient anatomy, healthcare system needs, and physician desires and enabling quick regulatory clearances, clinical implementation, and post-market surveillance by established relations with healthcare providers and government agencies.

Terumo Corporation is a prominent Japanese medical device maker that has an extensive cardiovascular business consisting of proprietary coronary stent systems that gained good penetration in the domestic market with local production allowing quick response to the customer needs in terms of feedback market (satisfaction and improvement in services). Approval standards are very strict at the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) to guarantee patient safety as well as facilitate innovation by providing accelerated approval processes to breakthrough technologies where the regulatory system balances stringent evaluation procedures with understanding that postponement in accessing a technology that would benefit patients risks subjecting them to unnecessary harm as other countries have already offered their consumers the benefit of a technology based on the latest generation. In May 2022, Biosensors International Group reported PMDA approval of BioFreedom Ultra with successful regulatory navigation, and polymer-free drug-coated stent with novel Biolimus A9 formulation has reached access to the Japanese market after successfully undergoing extensive clinical studies of safety and effectiveness in patient populations with characteristics the same as domestic demographics.

The existence of premium tier reimbursement of advanced stent technologies such as bioresorbable stents correlated with clinical outcomes provides solid avenues of future adoption, where value-based payment models that encourage the utilization of devices that have better clinical outcomes identified by lower rates of repeat revascularization, lower rates of stent thrombosis and better long-term patient results are justified by the increased cost of the initial procedural pick-up by downstream healthcare savings.

Category Wise Insights

By Product Type

Why Drug-Eluting Stents Lead the Market?

The largest and fastest expanding segment of the product is drug-eluting stents who dominate the Japanese market with a better clinical outcome, such as low restenosis rates (Its latest-generation formulations are now at target lesion revascularization rates of less than 5% at 1 year and 15-20% with BMS), that produced a strong clinical and economic value proposition. New drug-eluting scaffolds have advanced polymer-surface or polymer-free structures that release anti-proliferative drugs such as everolimus, zotarolimus, sirolimus analogues or paclitaxel that prevent in-stent restenosis by inhibiting hyperplasia of smooth muscle cells and their migration.

The development of successive generations of DES has dealt with early safety issues of late stent thrombosis with first-generation implants of durable polymers, with more modern formulations of biocompatible or biodegradable polymers that inhibit chronic inflammation, shorten the period of endothelialization that shortens the duration of dual antiplatelet therapy, and reduce the occurrence of very late thrombotic events years after implantation. The clinical evidence of better outcomes with drug-eluting stents is proven with a strong preference of Japanese interventional heart surgeons in most clinical settings with the cost factor balanced over the increased healthcare system costs and patient quality-of-life implications warranting high prices of new technologies.

Still with market shares of 34.0% in 2025, bare metal stents still have some specific clinical applications where they remain the best choice compared to DES, such as patients who need early discontinuation of dual antiplatelet therapy during planned surgery, have a high risk of bleeding, have an intolerance to certain medications, and are in resource constrained environments where lower cost stents are the best choice. Assurance that the outcomes can be predictable is ensured through the reliability and decades of clinical experience with bare metal stents, and the stainless steel and cobalt-chromium platforms have demonstrated that they have good mechanical properties, biocompatibility and long-term safety to continue to be used, especially in high volume centers with a variety of patients with different clinical presentations and risk factors.

By Application

Why Acute Myocardial Infarction Drives Stent Utilization?

The greatest application that drives demand for coronary stents is acute myocardial infarction which is a standard-of-care therapy in cases of ST-elevation myocardial infarction that need urgent revascularization to restore blood circulation, salvage myocardium, prevent cardiogenic shock, and lower mortality where time-to-treatment is a crucial determinant of outcomes.

The existence of well-established emergency medical services in Japan and 24/7 availability of catheterization laboratory in large cities, which results in prompt transport of STEMI patients and door-to-balloon times that are often below 90 minutes incorporating international guideline recommendations, which have led to the immediate implantation of stents that provide unquestionable mechanical reperfusion that is better than fibrinolytic therapy at reducing death, reinfarction, and major adverse cardiac events. Chronic total occlusion revascularization is an area of increasing application as well operator training, specific devices, and procedural strategies are expanding to achieve successful recanalization of totally blocked coronary arteries that were traditionally deemed unsuitable to percutaneous intervention, and drug-eluting stents are becoming of critical importance in maintaining patency in challenging procedures across long into occlusions through collateral vessels or antegrade wire manipulation. Stable and unstable angina patients are subjected to elective or urgent PCI according to the severity of the symptoms, ischemic load on stress testing, and anatomic disease complexity, and the decision to proceed with the intervention is made based on the fractional flow reserve, which means that able patients with bivariate lesions are treated and unnecessary procedures are avoided in the borderline stenoses, which can still be managed with optimal medical treatment.

By End User

Why Cardiac Catheterization Laboratories Lead Adoption?

Laboratories Cardiac catheterization laboratories dominate (36.5) in market share in 2025 with concentrated experience, specialized equipment, high PCI volumes and multidisciplinary modes of operation with an interventional cardiologist, cardiac nurse, radiologic technologist and support staff trained in complex coronary interventions, which demand advanced technical skills and immediate complication management capabilities. Large urban centers in Tokyo, Osaka, and other metro areas run high-volume catheterization laboratories with thousands of PCIs per year, and the experience of the procedures is directly proportional to the ability of the operator, the rates of complications, and the outcome of the procedure, which builds quality advantages for the specialized centers over low-volume facilities.

The capital infrastructure needed in the catheterization labs such as specialized fluoroscopies, hemodynamic monitoring systems, intravascular imaging systems, emergency cardiac surgery backup, and intensive care units, generates economies of scale that are beneficial to large-scale facilities in the amortization of fixed costs over high volumes of procedures while at the same time keeping up with current technologies and staff continuing training. Geographic differences pinpoint subtle growth trends as local infrastructure and demographic factors, Kyushu & Okinawa are projected to grow by 5.3% CAGR through 2035 on the back of modernizing healthcare facilities moving to meet the needs of the aging population, and modern medical tourism on the back of Okinawa's geographic advantages and governmental investment in cardiovascular capacity in the region will lead to a decrease in access inequalities between urban and rural areas.

Hospitals have a large market share with full cardiovascular services beyond catheterization such as cardiac surgery, heart failure care, cardiac rehabilitation, and chronic disease follow-up with coordinated care models that enhance outcomes with coordinated treatment plans, seamless progression of service, and teamwork of multidisciplinary teams to handle patients with multiple comorbidities.

Report Scope

Top Players in the Market

• Terumo Corporation

• Abbott Laboratories

• Medtronic plc

• Boston Scientific Corporation

• B. Braun Melsungen AG

• Biotronik SE & Co. KG

• MicroPort Scientific Corporation

• Cordis Corporation

• Cook Medical LLC

• Japan Medical Device Technology Co. Ltd.

• Others

Key Developments

• In October 2024: The DynamX bioadaptor stent, produced by Elixir medical showed breakthrough results in a Swedish trial that included 2,399 patients who showed reduced heart attacks, repeat procedures and cardiac death rates when using the DynamX bioadaptor stent as compared to traditional drug-eluting stents.

• In March 2024: AGENT IDE trial, which showed the reduced risk of failure of the target lesion by 38% with the use of the Agent paclitaxel-coated balloon, was approved.

• In January 2024: Olympus has acquired Taewoong Medical, a South Korean stent manufacturer, for USD 370 million as part of the strategy to widen the range of medical devices and increase revenue generation capacity.

The Japan Coronary Stents Market is segmented as follows:

By Product Type

• Bare Metal Stents

• Drug-Eluting Stents

o   Polymer-Based DES

o   Polymer-Free DES

• Bioresorbable Vascular Scaffolds

By Biomaterial

• Cobalt-Chromium

• Stainless Steel

• Platinum-Chromium

• Nickel-Titanium Alloy (Nitinol)

By Mode of Delivery

• Balloon-Expandable Stents

• Self-Expanding Stents

By Application

• Acute Myocardial Infarction

• Chronic Total Occlusion

• Stable Angina

• Unstable Angina

By End User

• Hospitals

• Cardiac Catheterization Laboratories

• Ambulatory Surgical Centers